No, it was discussed on the last CC: Emily Lee: Would

New Post Public Reply Private Reply Replies (0) Message Board
docj Beasley #13888
302
No, it was discussed on the last CC:

Emily Lee: Would you be able to give some color on the diagnostic testing? Are we devising
something there? Do we have any potential partners?
Joe Moscato: Yeah, that is a great question. Dr. Hal Hanes is on, so he can answer that who
runs our subsidiary NuGenerex diagnostics. There are tests right now, Emily,
that the CDC has made up. Those tests have to go to the lab. Obviously, our
technology with our diagnostic company is rapid testing, which can give a
response immediately. This is where it does not go to the lab and you are
waiting 24 to 48 hours to get a result. Hal, maybe you would like to go through
what you have been investigating, as well as what potential we have in creating
a rapid diagnostic handheld kit.
Dr. Hal Hanes: Sure Joe, thanks. That is a great question. If you think about what is happening
right now in China on the ground or in other potential high prevalent areas of
coronavirus infection, people are fearful. They are extremely fearful. You see
condo buildings being shut down in Hong Kong. You see whole cities in China
which have streets that are deserted except for necessities. The coronavirus
infection just basically starts out like a common cold or other infection, which
causes fever and sneezing. It is an upper respiratory virus infection. If you can
diagnose it at an early stage in the disease when people do have these initial
symptoms, you could very likely get them into isolation if they do have the
coronavirus. Make sure they are released if they do not have it. They are not a
danger. They can go home and do what they wish. Right now on incoming
airplanes from China, people are being isolated. You have looked at the news
about cruise ships where there is an outbreak, and the whole cruise ship is stuck
at a dock for two weeks or longer. This is to make sure there is no continual
spread.
Generex Investor Call Feb. 13, 2020
Page 30 of 31
Using Eric’s peptides, we can very likely and almost certainly develop an assay. It
would be an oral fluid assay in which a swab is taken from the throat, nose, or
upper respiratory tract. The virus can be detected directly from that swab on
our proprietary Express 2 platform. This test would take about 10 to 15 minutes
to read. It can be done by minimally trained personnel. They do not have to be
lab techs. They do not have to be nurses or doctors. It can be done in a clinic,
but it can also be used at points of entry by security agents. It is by anybody that
is trained a little bit in running the test. Simply take a swab, put it in the tube,
put the test in the swab of the tube, and it develops. That way people who get
into these high security areas can be screened quickly. By the way, most people
who have these symptoms do not have coronavirus.
There is a lot of overlapping symptomatology like the common cold or flu that
give you the same thing. Right now, if you are in those areas you think you
probably do have the coronavirus. We feel this is going to be a rapid test. It can
be done rapidly. It is cheap to produce once we have the proper peptides. It can
be administered universally practically anywhere. That was a great question
right there. Thanks.
Emily Lee: Is there a timeframe where this can be developed for the test tubes?
Dr. Hal Hanes: Yeah. I can give you an estimate. I certainly do not know. It would require us
taking the peptides that Eric produces and analyze this to make sure they are
proper ones. It is raising antibodies to them in animals. This can be done
relatively quickly. There are lots of animals where it can be done that way. Use
those antibodies as the analytical reagent. In other words, we put them on a
strip. It is like a diabetes strip, except for infectious diseases. We have a lot of
expertise in this. We put them on a strip. We have a control line. We put the
oral fluid after it has been diluted. Let it run up on the strip. The line with the
antibodies to the coronavirus, if there is a coronavirus in that sample, will light
up. The control line will light up. We will be able to say that person does not or
does have coronavirus. I would say probably once the peptides are fully
developed and we can immunize animals with them, there are many companies
that can do this rapidly. We should probably have an assay in three to four
months after those events occur.
Emily Lee: All right. Thank you so much. Are there any interested parties out there? For
example, is the Chinese government aware of this diagnostic test kit that you
guys are?
Dr. Hal Hanes: I think, Joe, you can answer this. I think this is part of the presentation to them
as an aside to the vaccine. Diagnosis goes hand-in-hand together with treatment
or vaccination. You have to have the diagnosis. The vaccination you can use for
everybody. We need to know the diagnosis for people to get treated properly.
Those who have had the virus probably do not need to get diagnosed.
Joe Moscato: Yeah, do not forget too. We are not treatment. We are vaccination.
Generex Investor Call Feb. 13, 2020
Page 31 of 31
Dr. Hal Hanes: Right. Right.
Joe Moscato: Treatment is like a Gilead product. You know? You have corona. You are very,
very sick. You are in a hospital. You have major symptomatic events going on.
Then they give you the Gilead product. Here, we are trying to guard against
severe symptoms at the very least. Guard against severe symptoms. This is all
the way up to full inoculations. That is something that we have discussed with
our Chinese partners. The big interest right now is the vaccine.
Emily Lee: I see. It just seemed like there was such a low supply of test kits. I would think
the test kit should be of great interest too. This is especially recently I read on
the news that some test kits provided to different states or cities are faulty in
the US. I would just think this could be a very huge opportunity.
Joe Moscato: Yeah, we feel the same exact way. I mean, in reality, doing the tests that are
now provided takes time. You have to send them to a lab. The lab has thousands
and thousands of these test kits, I am sure, based upon what is going on out
there. It is going to take time to get those diagnoses. Here, we have a rapid,
ready to go, in-hand test that lets you know five or ten minutes later if that
person is infected. Though we have not made great strides yet in figuring out
how to commercialize that for what is going on right now, the main focus has
been right now the vaccine.
Emily Lee: Okay yeah. Okay great. Thank you so much for your hard work. It sounds
wonderful what you guys are doing. I appreciate your hard work.

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

TCOM Secures $600M Deal to Boost NATO's Defense

Updated Category News Views 3

TCOM's Pivotal $600 Million Defense Contract How often do you hear about a deal north of $600 million that practically revamps a company's strategic future? That's precisely what's hitting the books at TCOM right now. They've scored a heavy-hitting Foreign Military Sales (FMS) contract to fortify NATO's eastern front with Poland. I'll tell you this—it’s one of the...

Continue Reading
Epson & The Photo Managers Highlight Memories in Sept.

Updated Category News Views 8

A Focus on Memory Preservation I remember a time when you kept memories in photo albums, dusty boxes in basements. Now, folks aim to digitize those moments before they're lost forever. With September here, Epson and The Photo Managers are telling us it's time for action. And hey, the campaign’s got a catchy name, 'One Photo, One Story.' Simple, yet it urges us all to...

Continue Reading
Zum Drivers Shine as New School Year Begins

Updated Category News Views 0

Opening the School Year with High Hopes Zum's crew of enthusiastic drivers hit the streets with a mission: kickstarting the new school year with a sense of excitement that feels fresh, even to a grizzled trader like me. These folks are doing more than just turning the ignition, they’re handling a vital cog in the education machine. From Fresno down to Rockford, you’ll...

Continue Reading
MacGregor's Bold Play: RoRo Tech for TT-Line's Ferries

Updated Category News Views 2

A Green Wave in the Baltic It looks like MacGregor's betting big on the future of maritime transport, and they're putting their chips down on TT-Line's next-gen battery-hybrid LNG ferries. With a contract fresh out of the oven, they've signed up to kit out these eco-warriors with a range of RoRo equipment. And let me tell you, this is no piddly order—by any stretch,...

Continue Reading
Supercharged Entertainment's Big Bet in Ohio's Polaris

Updated Category News Views 0

Fasten your seatbelts, folks—because there's a tinge of burnt rubber in the air at Columbus's Polaris Center. Supercharged Entertainment, the big guns in indoor karting, just kicked off construction at their brand-new venue, and it’s looking like a gearhead's paradise. A sprawling 16-acre parcel is set to become a haven for adrenaline junkies come Summer 2027. A Bold...

Continue Reading
Immunic Pushes Boundaries in MS with Vidofludimus

Updated Category News Views 1

Shaking Things Up in Multiple Sclerosis Therapy There's no telling how often the biotech sector tosses around the term 'game-changer,' but when Immunic's name comes up, more ears are perking up these days. The New York-based firm, waving the Nasdaq: IMUX flag, is lining up a virtual shindig come September 9, 2026, and for anyone invested in multiple sclerosis (MS) or...

Continue Reading
Axjo Group Expands in France with Eco-Tourets Buy

Updated Category News Views 6

Seizing the French Market: Axjo's Strategic Play Every now and then, you come across a company that's not just talking the talk but walking the green walk. Axjo Group's latest move—scooping up France's Eco-Tourets—puts them squarely in that league. It ain't just about expanding the footprint; it's about owning a piece of the future where sustainability isn't a...

Continue Reading
Tradr's Bold Venture: Anthropic ETFs Ahead of IPO

Updated Category News Views 2

Why Tradr Is Diving Into Anthropic's Hype There's a whiff of anticipation in the air as Anthropic gears up for its much-anticipated IPO, and Tradr isn't sitting on its hands here. They've just filed for two ETFs—one long, one short—ahead of the big day. We're talking about ANTT and ANTZ, betting on leveraged and inverse plays on whatever whirlwind Anthropic's stock...

Continue Reading
Early Education's Massive Impact: Key Skills for Success

Updated Category News Views 2

Unlocking Lifelong Success: The Early Advantage Ever look at a successful adult and wonder, "Where'd they get that spark?" According to HelloNation and child care expert Karen Ego, it all starts early. Think of early learning not just as prepping for school, but as the first blueprint for life's journey. It's the skills you pick up in those tender years that stick it out...

Continue Reading
Innventure Faces Class Action Over Alleged Deception

Updated Category News Views 3

Unpacking the Innventure Debacle Innventure, Inc. (NASDAQ:INV) seems to have landed itself in hot water, and not the relaxing kind. The revelation that its grand AI data center project in Ontario might never have existed has stirred up quite a storm among shareholders. This isn't just some run-of-the-mill oversight. We're talking about allegations of concocted stories...

Continue Reading

Top 5 Most Recently Viewed Articles

Zealand Pharma A/S Updates Share Count and Voting Rights

Updated Category News Views 86

Zealand Pharma A/S, a key player in the biotech sector out of Copenhagen, confirmed back in early 2024 that it had a total of 71,023,871 shares outstanding. Each share carries a nominal value of DKK 1. This number isn’t just a footnote—it’s vital for any stakeholder keeping tabs on their stake or those considering diving into this space. The company’s compliance...

Continue Reading
CS Genetics Introduces Innovative SimpleCell™ Genomics Kits

Updated Category News Views 146

CS Genetics Launches SimpleCell™ for Enhanced Single-Cell Genomics Single-cell genomics has entered a new era with the exciting launch of SimpleCell™ 3' Gene Expression kits by CS Genetics, a pioneer in the field. This innovative platform simplifies the process of single-cell transcriptomics, making it more accessible and scalable than ever before. The Power of...

Continue Reading
LifeMD's Engagement at the Upcoming Growth Conference

Updated Category News Views 117

LifeMD's Participation in a Major Growth Conference LifeMD, Inc. (Nasdaq: LFMD), a prominent provider in the domain of virtual primary healthcare, has announced its upcoming participation in the Canaccord Genuity 45th Annual Growth Conference. This well-regarded event will take place from August 12 to 14, offering a dynamic platform for dialogue between investors and...

Continue Reading
Exploring Embedded Finance in India: Growth Forecasts to 2029

Updated Category News Views 306

The Future of Embedded Finance in India The embedded finance industry in India is on a remarkable growth trajectory. As we look ahead to the years leading up to 2029, projections indicate a compound annual growth rate (CAGR) of 37.8%, with revenue climbing from US$5.75 billion in 2024 to an impressive US$28.6 billion by the end of the forecast period. Transformative...

Continue Reading
Revolutionizing 3D Modeling: Fixstars Unveils CUMVS Software

Updated Category News Views 179

Revolutionizing 3D Modeling with CUMVS Software Fixstars Corporation, a leader in AI-driven software development, recently made waves with the open-source release of its groundbreaking software, CUMVS (cuda-multi-view-stereo), designed for rapid 3D model generation from 2D images. This innovative software allows users to create digital twins of real-world objects, marking...

Continue Reading